Join
Live feed
·
INSIDERFilingvia Quantisnow
Zentalis Pharmaceuticals Inc. logo

Director Johnson David Michael was granted 57,603 shares, increasing direct ownership by 30% to 250,421 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ZNTL· Zentalis Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZNTL (Zentalis Pharmaceuticals Inc.) and more on Quantisnow.